Fighting Disease with Technology
We’re pioneering the use of infrared and ultrasound to safely and effectively treat the world’s most devastating diseases.
Open Source, Always - AGPL, CC BY SA-4.0 and our Patent Pledge
How it works
Picture an opera singer shattering a wine glass.
Our approach is similar: We manipulate the phase of infrared light, ultrasound, and electromagnetic waves to enable potential diagnosis and treatment of diseases through manipulation or destruction of cells individually without harming surrounding tissue.
Early results on cancer, depression, stroke, and more:
Access our technology
Reserve one of our research platforms now.
Or, access our open source technology.
You can customize the platform for utilization in the disease state you wish to study further. The order reservation is $100 and fully refundable at any time for any reason. The actual R&D device kit price will be $10,000 and is expected to start shipping in Q2 2025. We are communicating regularly with those that have put in orders and you can come to our labs and see the functioning devices.
A revolution in care
Progress at the speed of technology
Our tech-driven approach leverages software, hardware and AI over costly, slow to develop, and imprecise* pharmaceuticals
* that deliver medication to the whole body in lieu of solely the region needing treatment
That means we can iterate at the speed of consumer electronics, making treatment cheaper, better, and more accessible year after year.
Our Goal: Healing without harm
Infrared light and ultrasound have been used safely on billions of people — including fetuses — for a century.
We use them non-invasively to target disease without the side effects of ionizing radiation or pharmaceuticals.
Novel method, new cures
Our approach is a breakthrough. We have shown we can selectively target diseased cells without harming surrounding tissue in mice. It’s a new method with incredible potential.
This opens the door to treatment for a wide range of currently incurable conditions, including cancer, severe depression, and stroke.
This notification serves as a safety disclosure for our Open-LIFU and Open-Motion systems intended exclusively for research purposes. Openwater's platform has not received FDA clearance or approval for commercial distribution.